X-ZELL selected as finalist for prestigious Hello Tomorrow Singapore Challenge

Singapore, October 2019 – X-ZELL has been nominated as one of 16 regional finalists of the 2019 Hello Tomorrow Singapore Challenge.

Hello Tomorrow is a global non-profit organisation on a mission to accelerate deep technology research and entrepreneurship, and to bring breakthrough innovation to commercial scale.

Headquartered in Paris, France, it can draw on a network of six regional hubs around the world, with Hello Tomorrow Singapore serving as the gateway to Southeast Asia, Hong Kong and Taiwan. 

The annual Hello Tomorrow Singapore Regional Challenge is held as part of the Hello Tomorrow Global Challenge, the largest deep-tech startup competition globally.

It was designed to back innovative ideas with the resources, energy and network required to make them a reality and bring positive change to our planet.

X-ZELL was selected from a pool of more than 500 applicants from across Asia to demonstrate the company’s ground-breaking work on AI-guided cell analytics for early cancer detection.

The regional Hello Tomorrow Challenge Finale will be held as part of the highly anticipated Hello Tomorrow Summit on 7 November 2019 at the Capitol in Singapore.

The finalists will present on the Innovation Stage between 11:10am and 14:50pm.

Date:               7 Nov 2019
Venue:            Capitol Singapore
More:              www.hello-tomorrow.sg

Media Contact:
Sebastian Grote
Head of Strategy, Marketing & Communications
+65 9630 0706


About X-ZELL
Recurrently ranked among the most innovative health technology start-ups in Asia, X-ZELL is fusing next-generation cell detection technology with cutting-edge Artificial Intelligence to isolate and visualise ultra-rare cells in blood and frozen tissue. Established in Bangkok, Thailand, the company recently made global headlines when it demonstrated the ability to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in small, 10mL blood samples. Widely considered one of the most promising biomarkers for the early detection of clinically significant cancers, tCEC had previously been classified as undetectable in clinical routine. Now headquartered in Singapore, X-ZELL is aiming to make tCEC-based cancer screening accessible to patients around the globe – making the young company one of the promising names in the booming cancer prevention space.


















© 2022 X-ZELL INC

Find Us